Summary Polyplus-Transfection SA (Polyplus) is a biotechnology company that develops and markets solutions for in vivo and in vitro delivery of nucleic acids in research, bioproduction and therapeutics.The company develops RNA interference such as STICKY SIRNA and SIRNAPLUS for in vivo research.
It develops transfection reagents such as JetPRIME, JetPEI, PEIpro, INTERFERin, PULSin, JetMESSENGER and ZNA, among others.Polyplus also provides reagents for preclinical and clinical trials.
The company’s products find application in gene expression, RNA interference, protein production, in vivo delivery, virus production, molecular biology and diagnostics, genome editing and protein delivery.It has operations in France and the US.
Polyplus is headquartered in Strasbourg, France.
Polyplus-Transfection SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
The microfluidics market is projected to grow at a CAGR of 22.9%. The global microfluidics market size is projected to reach USD 44.0 billion by 2025 from USD 15.7 billion in 2020, at a CAGR of 22.9% during the forecast period. The ability of the microfluidics technology to replicate all the functions of its traditional counterparts in...
Rising focus on the analytical testing of biologics and biosimilars to drive market growth The global bioanalytical testing services market is projected to reach USD 3.7 billion by 2025 from USD 2.1 billion in 2020, at a CAGR of 11.8% during the forecast period. The growth in this market is attributed to the rising focus...
The Global Cancer Diagnostics Partnering 2014-2020 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer diagnostics partnering deals Disclosed headlines, upfronts, milestones and royalties by...
The Global Stem Cell Partnering Terms and Agreements 2010-2020 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in stem cell partnering Deal terms analysis Partnering agreement structure Partnering...
Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H1 2020 Summary Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that...
Growth/Differentiation Factor 8 - Pipeline Review, H1 2020 Summary According to the recently published report ’GrowthDifferentiation Factor 8 - Pipeline Review, H1 2020’; Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 9 molecules. Growth/Differentiation...
Rosacea - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H1 2020, provides an overview of the Rosacea (Dermatology) pipeline landscape. Rosacea is a chronic and potentially life-disruptive disorder primarily of the...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.